Unilever also reiterates its commitment to continuing to improve the performance of its existing portfolio through its ongoing focus on operational excellence, its upcoming reorganization and by rotating the portfolio to higher growth categories." The company said it would give an update on its fourth-quarter and full-year performance on Feb. 10. A chorus of financial analysts had argued the acquisition would destroy value for Unilever shareholders, and that the group had little to gain by buying — and attempting to scale — over the counter drugs, vitamins and supplements.